FILING ANALYSIS · TUESDAY, NOVEMBER 10
Protalix BioTherapeutics, Inc. PLX — 8-K: Results of Operations and Financial Condition
positive
The company reported a net income of $4.0 million for the third quarter and $26.1 million for the nine months ended September 30, 2026, with total revenues increasing by $32.0 million year to date to $75.6 million. Management expects to meet or exceed 2026 guidance for total revenues of approximately $78.0 million to $83.0 million.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →